Cannabinoids in experimental stroke: A systematic review and meta-analysis

Journal of Perinatology

Volumn 35, Issue 3, 2015, Pages 348-358

  England, Timothy J ^a   Hind, William H ^a   Rasid, Nadiah A ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

cannabinoid; meta analysis; neuroprotection; preclinical; stroke

Indexed keywords

CANNABIDIOL; CANNABINOID; DRONABINOL; ENDOCANNABINOID; LIGAND; NEUROPROTECTIVE AGENT;

ACUTE DRUG ADMINISTRATION; BRAIN INFARCTION SIZE; EXPERIMENTAL STROKE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLISHING; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; ANIMAL; BRAIN; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; DRUG EFFECTS; PATHOLOGY;

ANIMALS; BRAIN; CANNABINOIDS; DISEASE MODELS, ANIMAL; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84938508710     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.218     Document Type: Review

References (62)

1. Jin KL, Mao XO, Goldsmith PC, Greenberg DA. CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000; 48: 257-261.
2. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I et al. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 2007; 412: 114-117.
3. Mishima K, Hayakawa K, Abe K, Ikeda T, Egashira N, Iwasaki K et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptordependent mechanism. Stroke 2005; 36: 1077-1082.
4. Schabitz WR, Giuffrida A, Berger C, Aschoff A, Schwaninger M, Schwab S et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 2002; 33: 2112-2114.
5. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004; 129: 743-750.
6. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23: 7767-7775.
7. Degn M, Lambertsen KL, Petersen G, Meldgaard M, Artmann A, Clausen BH et al. Changes in brain levels of N-Acylethanolamines and 2-Arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem 2007; 103: 1907-1916.
8. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC et al. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids Health Dis 2010; 9: 47.
9. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 2010; 24: 788-798.
10. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 2003; 34: 2000-2006.
11. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF et al. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 2008; 152: 753-760.
12. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Ogata A, Fujioka M et al. Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamicindependent hypothermia. Life Sci 2007; 80: 1466-1471.
13. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 2010; 62: 588-631.
14. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
15. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
16. Gibson CL, Gray LJ, Bath PM, Murphy SP. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 2008; 131: 318-328.
17. England TJ, Gibson CL, Bath PM. Granulocyte-colony stimulating factor in experimental stroke and its effects on infarct size and functional outcome: a systematic review. Brain Res Rev 2009; 62: 71-82.
18. Ahmad A, Genovese T, Impellizzeri D, Crupi R, Velardi E, Marino A et al. Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res 2012; 1477: 45-58.
19. Bonfils PK, Reith J, Hasseldam H, Johansen FF. Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia. Neurochem Int 2006; 49: 508-518.
20. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH et al. Massive accumulation of N-Acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 2004; 88: 1159-1167.
21. Belayev L, Busto R, Zhao W, Ginsberg MD. HU-211, a novel noncompetitive N-methyl-D-Aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 1995; 26: 2313-2319, discussion 2319-20.
22. Belayev L, Busto R, Watson BD, Ginsberg MD. Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: a quantitative study. Brain Res 1995; 702: 266-270.
23. Garg P, Duncan RS, Kaja S, Koulen P. Intracellular mechanisms of N-Acylethanolamine-mediated neuroprotection in a rat model of stroke. Neuroscience 2010; 166: 252-262.
24. Garg P, Duncan RS, Kaja S, Zabaneh A, Chapman KD, Koulen P et al. Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke. Neurosci Lett 2011; 492: 134-138.
25. Hu B, Wang Q, Chen Y, Du J, Zhu X, Lu Y et al. Neuroprotective effect of WIN 55212-2 pretreatment against focal cerebral ischemia through activation of extracellular signal-regulated kinases in rats. Eur J Pharmacol 2010; 645: 102-107.
26. Lavie G, Teichner A, Shohami E, Ovadia H, Leker RR. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res 2001; 901: 195-201.
27. Leker RR, Shohami E, Abramsky O, Ovadia H. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 1999; 162: 114-119.
28. Murakami K, Suzuki M, Suzuki N, Hamajo K, Tsukamoto T, Shimojo M et al. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats. Brain Res 2013; 1526: 84-93.
29. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-2995.
30. Schomacher M, Muller HD, Sommer C, Schwab S, Schabitz WR. Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. Brain Res 2008; 1240: 213-220.
31. Sun J, Fang Y, Chen T, Guo J, Yan J, Song S et al. WIN55212-2 promotes differentiation of oligodendrocyte precursor cells and improve remyelination through regulation of the phosphorylation level of the ERK 1/2 via cannabinoid receptor 1 after stroke-induced demyelination. Brain Res 2013; 1491: 225-235.
32. Sun J, Fang YQ, Ren H, Chen T, Guo JJ, Yan J et al. WIN55212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats. Acta Pharmacol Sin 2013; 34: 119-128.
33. Suzuki N, Suzuki M, Hamajo K, Murakami K, Tsukamoto T, Shimojo M et al. Contribution of hypothermia and CB1 receptor activation to protective effects of TAK-937, a cannabinoid receptor agonist, in rat transient MCAO model. PLoS ONE 2012; 7: e40889.
34. Teichner A, Ovadia H, Lavie G, Leker RR. Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect? Exp Neurol 2003; 182: 353-360.
35. Hayakawa K, Irie K, Sano K, Watanabe T, Higuchi S, Enoki M et al. Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism. Biol Pharmaceutical Bull 2009; 32: 1538-1544.
36. Hayakawa K, Mishima K, Abe K, Hasebe N, Takamatsu F, Yasuda H et al. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 2004; 15: 2381-2385.
37. Hayakawa K, Mishima K, Irie K, Hazekawa M, Mishima S, Fujioka M et al. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008; 55: 1280-1286.
38. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M et al. Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem 2007; 102: 1488-1496.
39. Hayakawa K, Mishima K, Nozako M, Ogata A, Hazekawa M, Liu AX et al. Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Neuropharmacology 2007; 52: 1079-1087.
40. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 2007; 152: 734-743.
41. Zarruk JG, Fernandez-Lopez D, Garcia-Yebenes I, Garcia-Gutierrez MS, Vivancos J, Nombela F et al. Cannabinoid type 2 receptor activation downregulates strokeinduced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 2012; 43: 211-219.
42. Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF et al. CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res 2009; 78: 86-94.
43. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF et al. 2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 2007; 27: 1387-1396.
44. Zhou Y, Yang L, Ma A, Zhang X, Li W, Yang W et al. Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-Activated receptor alpha. Neuropharmacology 2012; 63: 242-249.
45. Suzuki N, Suzuki M, Murakami K, Hamajo K, Tsukamoto T, Shimojo M et al. Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res 2012; 1430: 93-100.
46. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
47. Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16: 4322-4334.
48. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002; 22: 9771-9775.
49. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
50. Raffa RB, Ward SJ. CB. (1)-independent mechanisms of Delta(9)-THCV, AM251 and SR141716 (rimonabant). J Clin Pharm Ther 2012; 37: 260-265.
51. Zechariah A, ElAli A, Hermann DM. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 2010; 41: 1008-1012.
52. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-2250.
53. Electronic Medicines Compendium Sativex: Summary of Product Charactreristics http://www.medicines.org.uk/emc/medicine/23262.
54. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013; 260: 984-997.
55. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010; 13: 421-432.
56. Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML et al. Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 2008; 64: 966-973.
57. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36: 1219-1226.
58. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; 3: Cd009270.
59. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010; 8: e1000344.
60. Crossley NA, Sena E, Goehler J, Horn J, van der Worp B, Bath PM et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008; 39: 929-934.
61. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006: 467-477.
62. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-459.